NEW YORK (GenomeWeb News) – The Ontario Genomics Institute said today that it has provided funding to Tissue Regeneration Therapeutics (TRT), a company developing umbilical stem cell-based treatments for a range of diseases, that will support 'omics-based research projects.

OGI and the company did not disclose the amount of the investment. The funds will support proteomic and transcriptomic analyses that will provide information the firm will need to gain the regulatory approval to conduct human clinical trials and to differentiate their product from competitors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.